SPL 2.06% 9.5¢ starpharma holdings limited

Sanofi Annual Report 2022, page-11

  1. 12,921 Posts.
    lightbulb Created with Sketch. 1451
    Further to my earlier comment....Sandoz's Cabazitaxel is a generic version of Sanofi's Jevtana

    Starpharma's Dep Cabazitaxel is a new patented formulation

    IT IS NOT A GENERIC

    And once it gets to market will be generating billions of dollars in revenue

    I would have thought you'd know this @col69
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.